



Republic of the Philippines
Department of Health
OFFICE OF THE SECRETARY

**MEDICINES RECOMMENDED FOR THE NON- INCLUSION IN THE PHILIPPINE
NATIONAL FORMULARY (PNF)**

As of 04 March 2022, the Health Technology Assessment Council (HTAC) has finished the assessment and deliberation of rituximab 1400 mg/ 11.7 mL solution for subcutaneous (SC) injection for the treatment of non-Hodgkin's lymphoma.

The HTAC hereby makes public the **preliminary recommendation for the non-inclusion of rituximab 1400 mg/ 11.7 mL solution for subcutaneous (SC) injection for the treatment of non-Hodgkin's lymphoma** in the attached Evidence Summary accessible at this link (<https://tinyurl.com/ES-RituxSC-Prelim>) with supporting studies informing their recommendation. All comments, inputs and/or appeals using the template from the Philippine HTA Process Guide (<http://bit.ly/HTAPGPhilippines>) may be submitted until **18 March 2022** for consideration of the HTAC through email at hta@doh.gov.ph.

Should you wish to submit hard copies of your submissions, you may drop them off at the 4th floor, Philippine Blood Disease and Transfusion Center, Lung Center Compound, Quezon Avenue, Quezon Avenue, Quezon City. Appeals shall no longer be entertained after the prescribed deadline.



ANNA MELISSA S. GUERRERO, MD, MPH (HTA)
Head, Health Technology Assessment Unit
Health Regulation Team